MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide

MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide is a combination cancer vaccine regimen designed to stimulate an immune response against melanoma antigens. The core component, MELITAC 12.1, is a synthetic peptide vaccine composed of an emulsion containing twelve class I MHC-restricted melanoma peptides and a class II MHC-restricted tetanus toxoid helper peptide[1][4][8]. The formulation is typically administered in a water-in-oil emulsion with the adjuvant Montanide ISA-51 and may include additional immunostimulatory agents such as lipopolysaccharide (LPS), which acts as a Toll-like receptor agonist to further enhance immune activation[3][4]. This combination aims to induce robust CD8+ T cell responses targeting melanoma cells, with the adjuvants serving to boost antigen presentation and overall immunogenicity[5]. Clinical trials have evaluated this regimen primarily for advanced or recurrent melanoma.

Other names

MELITAC 12.1 peptide vaccineMELITAC12.1 peptide vaccineMELITAC-12.1 peptide vaccine